SSY Group Gets China Nod for Registration of Asthma, Bronchitis Drug for Bulk Preparations

MT Newswires Live

2025/11/24

SSY Group (HKG:2005) obtained production and registration approval for the Aminophylline Tablets from China's National Medical Products Administration to become a bulk drug for preparations on the market, a Monday Hong Kong bourse filing said.

The move came as the drug is regarded as passing the regulator's consistency evaluation.

The drug is mainly used to relieve wheezing symptoms in bronchial asthma, wheezing bronchitis, and obstructive emphysema, and to treat asthma caused by cardiogenic pulmonary edema.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2585464734"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585464734\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585464734?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585464734","market":"sg","top_or_hot":-1,"title":"SSY Group Gets China Nod for Registration of Asthma, Bronchitis Drug for Bulk Preparations","media":"MT Newswires Live","content":"<html><body><p> SSY Group (HKG:2005) obtained production and registration approval for the Aminophylline Tablets from China's National Medical Products Administration to become a bulk drug for preparations on the market, a Monday Hong Kong bourse filing said.</p><p>The move came as the drug is regarded as passing the regulator's consistency evaluation.</p><p>The drug is mainly used to relieve wheezing symptoms in bronchial asthma, wheezing bronchitis, and obstructive emphysema, and to treat asthma caused by cardiogenic pulmonary edema.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group Gets China Nod for Registration of Asthma, Bronchitis Drug for Bulk Preparations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group Gets China Nod for Registration of Asthma, Bronchitis Drug for Bulk Preparations\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-11-24 20:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> SSY Group (HKG:2005) obtained production and registration approval for the Aminophylline Tablets from China's National Medical Products Administration to become a bulk drug for preparations on the market, a Monday Hong Kong bourse filing said.</p><p>The move came as the drug is regarded as passing the regulator's consistency evaluation.</p><p>The drug is mainly used to relieve wheezing symptoms in bronchial asthma, wheezing bronchitis, and obstructive emphysema, and to treat asthma caused by cardiogenic pulmonary edema.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSY","symbol_name":"Sunlink Health Systems Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2585464734","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585464734","pubTimestamp":1763988646,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"SSY Group  obtained production and registration approval for the Aminophylline Tablets from China's National Medical Products Administration to become a bulk drug for preparations on the market, a Monday Hong Kong bourse filing said.The move came as the drug is regarded as passing the regulator's consistency evaluation.The drug is mainly used to relieve wheezing symptoms in bronchial asthma, wheezing bronchitis, and obstructive emphysema, and to treat asthma caused by cardiogenic pulmonary edema.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SSY":"Sunlink Health Systems Inc","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","BK4185":"保健护理机构","BK1191":"制药","02005":"石四药集团"},"translate_title":"SSY集团获得中国批准哮喘、支气管炎原料药注册","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1,"SSY":1.5},"content_text":"SSY Group (HKG:2005) obtained production and registration approval for the Aminophylline Tablets from China's National Medical Products Administration to become a bulk drug for preparations on the market, a Monday Hong Kong bourse filing said.The move came as the drug is regarded as passing the regulator's consistency evaluation.The drug is mainly used to relieve wheezing symptoms in bronchial asthma, wheezing bronchitis, and obstructive emphysema, and to treat asthma caused by cardiogenic pulmonary edema.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}